Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million
09 Settembre 2020 - 6:30PM
Valneva Announces New IXIARO® Supply Contract with the US
Government worth up to $166 million
Saint Herblain (France), September 9,
2020 – Valneva SE (“Valneva”), a specialty vaccine
company, today announced the signing of a new contract, lasting up
to three years, with the U.S. government Department of Defense
(DoD) for the supply of its Japanese encephalitis (JE) vaccine
IXIARO®.
The new contract spans a total of three years
(one base year, plus two option years) with a base-year value of
$61 million. The DoD has the option to purchase a total of $76
million - $105 million worth of IXIARO® across the two option
years. Deliveries for the base-year will commence in the
fourth quarter 2020.
Franck Grimaud, Chief Business Officer
of Valneva commented, “We are very pleased with this new
contract including the longer duration of up to three years – a
clear demonstration of the clinical need for personnel deployed to
JE endemic areas. The U.S. military has been using IXIARO® for
the past ten years and we are excited to continue to help protect
military personnel, their families, civilian government service
personnel, and government contractors from this potentially deadly
disease.”
IXIARO® is the only JE vaccine approved by the
U.S. Food and Drug Administration (FDA), having been developed
through a cooperative research and development agreement with the
Walter Reed Army Institute of Research. Valneva markets and
distributes IXIARO® directly to the U.S. military and U.S. private
market.
About IXIARO®/JESPECT®
Valneva’s Japanese encephalitis vaccine is
indicated for active immunization for the prevention of the disease
for people who travel to, or live in, endemic areas. It has
received marketing approval in the U.S., Europe, Canada, Hong Kong,
Singapore, and Israel under the trade name IXIARO® and in Australia
and New Zealand where it is marketed as JESPECT®. It is the only
vaccine available to the U.S. military for Japanese Encephalitis.
IXIARO® is approved for use in individuals two months of age and
older in the U.S. and EU member states, Canada, Norway,
Liechtenstein, Iceland, Singapore, Hong Kong, Japan, the Republic
of Korea and Israel. In all other licensed territories,
IXIARO®/JESPECT® is indicated for use in persons aged 18 years or
more.
About Japanese Encephalitis
Japanese encephalitis is a deadly infectious
disease found mainly in Asia. About 70,000 cases of JE are
estimated to occur in Asia each year, although the actual number of
cases is likely much higher due to underreporting in rural areas.
JE is fatal in approximately 30 percent of those who show symptoms,
and leaves half of survivors with permanent brain damage. The
disease is endemic in Southeast Asia, India and China, a region
with a population of more than three billion. In 2005, JE killed
more than 1,200 children in only one month during an epidemic
outbreak in Uttar Pradesh, India, and Nepal.
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. Valneva’s portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has various vaccines in
development including unique vaccines against Lyme disease,
chikungunya and COVID-19. Valneva has operations in Austria,
Sweden, the United Kingdom, France, Canada and the US with over 500
employees. For more information, visit www.valneva.com and
follow the Company on LinkedIn.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_09_09_VLA_IXIARO_DoD_Contract_PR_EN_Final
Grafico Azioni Valneva (EU:VLA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Valneva (EU:VLA)
Storico
Da Apr 2023 a Apr 2024